Inquiry Basket
Loading ......
Ocrelizumab is a humanized immunoglobulin gamma one (IgG1) monoclonal antibody that targets CD20, a cell surface antigen expressed primarily on mature B lymphocytes. By binding to CD20, Ocrelizumab induces B-cell depletion through antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct apoptosis. This targeted elimination of CD20-positive B cells underlies the therapeutic efficacy of Ocrelizumab in multiple sclerosis (MS), a chronic autoimmune disorder of the central nervous system characterized by demyelination, axonal damage, and progressive neurological disability.The mechanism of Ocrelizumab differs from other anti-CD20 antibodies through its humanized structure and optimized Fc region, which enhances binding to Fc gamma receptors on immune effector cells while reducing immunogenicity compared to chimeric alternatives. The dosing regimen involves intravenous infusions every six months following initial loading doses, providing sustained B-cell depletion with convenient twice-yearly administration. The successful clinical use of Ocrelizumab depends on robust bioanalytical methods to support pharmacokinetic studies, immunogenicity assessments, and therapeutic monitoring. Unlike conventional monoclonal antibody assays that measure only total drug concentration, Ocrelizumab bioanalysis requires differentiation between free drug and drug bound to its target (CD20-expressing cells or soluble CD20). Additionally, detection of anti-Ocrelizumab antibodies is critical for evaluating immunogenicity and understanding individual patient responses.
Figure 1.Ocrelizumab ELISA Kit Complete Bioanalytical Solutions for Therapeutic Monitoring.
The pathogenesis of multiple sclerosis involves complex interactions between various immune cell types. While T cells have traditionally been considered the primary drivers of MS pathology, accumulating evidence has established that B cells play a critical and non-redundant role in disease progression. B cells contribute to MS pathogenesis through multiple mechanisms including autoantibody production, antigen presentation to T cells, pro-inflammatory cytokine secretion, and formation of ectopic lymphoid follicles within the meninges. The presence of B cells and plasma cells in the cerebrospinal fluid and brain lesions of MS patients has been well documented. Clonally expanded B cells within the central nervous system produce oligoclonal immunoglobulin bands, a diagnostic hallmark of MS. The success of B-cell depleting therapies in MS has definitively established the importance of B cells in disease pathogenesis.
Ocrelizumab binds specifically to CD20, a transmembrane protein expressed on pre-B cells, mature B cells, and memory B cells, but not on plasma cells or hematopoietic stem cells. This selective expression pattern allows Ocrelizumab to deplete pathogenic B cells while preserving the ability to generate new B cells from precursor populations and maintain pre-existing humoral immunity through long-lived plasma cells. Upon binding to CD20, Ocrelizumab engages immune effector mechanisms that result in B-cell destruction. The humanized IgG1 Fc region of Ocrelizumab has been optimized for enhanced binding to Fc gamma receptor IIIa on natural killer cells and macrophages, potentiating antibody-dependent cellular cytotoxicity. Additionally, Ocrelizumab activates the complement cascade, leading to complement-dependent cytotoxicity, and can directly induce apoptotic cell death through signaling pathways.
In relapsing-remitting multiple sclerosis, Ocrelizumab has demonstrated superior efficacy compared to interferon beta-1a, a standard first-line therapy. Clinical trials showed significant reductions in annualized relapse rates, disability progression, and magnetic resonance imaging disease activity. The magnitude of benefit was consistent across patient subgroups. In primary progressive multiple sclerosis, Ocrelizumab represents the first therapy shown to slow disability progression. Patients treated with Ocrelizumab had a lower risk of confirmed disability progression compared to placebo, with benefits observed across multiple measures of disease activity and progression. This approval fundamentally changed the treatment landscape for PPMS patients who previously had no effective therapeutic options.
The Free Ocrelizumab ELISA Kit is specifically designed for the quantitative determination of unbound Ocrelizumab concentrations in human serum or plasma. This kit measures the pharmacologically active fraction of drug available for target engagement.
The Total Ocrelizumab ELISA Kit is designed for the quantitative determination of total Ocrelizumab concentrations in human serum or plasma, including both free drug and CD20-bound drug.
Ocrelizumab is a highly effective CD20-targeting therapy for both relapsing and progressive forms of multiple sclerosis, representing a major advance in MS treatment. The unique bioanalytical requirements of Ocrelizumab—including differentiation between free and total drug—necessitate specialized ELISA solutions. The Free Ocrelizumab ELISA Kit measures the pharmacologically active fraction available for B-cell engagement. The Total Ocrelizumab ELISA Kit provides comprehensive exposure assessment including both free and CD20-bound drug. The Anti-Ocrelizumab ELISA Kit enables reliable immunogenicity detection for regulatory submissions. Together, these three kits provide a complete bioanalytical toolkit for researchers and clinicians working with Ocrelizumab across all stages of development and clinical use.
| Cat. No. | Product Name | Species Reactivity | Detection Method | |
| DEIA-JY25024 | Free Ocrelizumab ELISA Kit | Human | ELISA | Inquiry |
| DEIA-JY25042 | Total Ocrelizumab ELISA Kit | Human | ELISA | Inquiry |
| DEIA-JY25060 | Anti-Ocrelizumab ELISA Kit | Human | ELISA | Inquiry |
Loading ......
